MedChemExpress LLC (MCE)
29481 products found
MedChemExpress LLC (MCE) products
MedChemExpress - Model Streptonigrin (Bruneomycin) - 3930-19-6
Streptonigrin (Bruneomycin), a natural product produced by Streptomyces flocculus, possesses both anti-tumor and anti-bacterial activity. Streptonigrin acts as a pan-PAD inhibitor with IC50s of 48.3±34.2 µM, 26.1±0.3 µM, 0.43±0.03 µM, and 2.5±0.4 µM for PAD1, PAD2, PAD3, and PAD4, respectively.MedChemExpress - Model RMC-6236 - 2765081-21-6
RMC-6236 (Compound A122) is a potent RAS(ON)MULTI inhibitor and can be used for the research of cancer[1].MedChemExpress - Model Datopotamab deruxtecan - 2238831-60-0
Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan has a potent antitumor activity[1].MedChemExpress - Model Trastuzumab deruxtecan - 1826843-81-5
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer[1][2].MedChemExpress - Model Deruxtecan - 1599440-13-7
Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and amaleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.MedChemExpress - Model Sacituzumab govitecan - 1491917-83-9
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity[1].MedChemExpress - Model Adagrasib - 2326521-71-3
Adagrasib (MRTX849) is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity. Adagrasib covalently binds to KRAS G12C at the cysteine at residue 12, locks the protein in its inactive GDP-bound conformation, and inhibits KRAS-dependent signal transduction[1][2].MedChemExpress - Model Capivasertib - 1143532-39-1
Capivasertib (AZD5363) is an orally active and potent pan-AKT kinase inhibitor with IC50 of 3, 7 and 7 nM for Akt1,Akt2 and Akt3, respectively.MedChemExpress - Model Revumenib - 2169919-21-3
Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)[1].